Price T Rowe Associates Inc Monte Rosa Therapeutics, Inc. Transaction History
Price T Rowe Associates Inc
- $869 Billion
- Q3 2024
A detailed history of Price T Rowe Associates Inc transactions in Monte Rosa Therapeutics, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 6,601,141 shares of GLUE stock, worth $55.2 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
6,601,141
Previous 5,977,587
10.43%
Holding current value
$55.2 Million
Previous $22.4 Million
56.49%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding GLUE
# of Institutions
83Shares Held
43.9MCall Options Held
141KPut Options Held
31.2K-
Nea Management Company, LLC Timonium, MD7.69MShares$64.3 Million3.11% of portfolio
-
Avoro Capital Advisors LLC New York, NY5.79MShares$48.4 Million0.46% of portfolio
-
Baker Bros. Advisors LP New York, NY4.92MShares$41.1 Million0.28% of portfolio
-
Suvretta Capital Management, LLC New York, NY2.66MShares$22.2 Million0.55% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.53MShares$21.2 Million0.0% of portfolio
About Monte Rosa Therapeutics, Inc.
- Ticker GLUE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,713,900
- Market Cap $391M
- Description
- Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing prot...